作者: Lucilla Steinaa , Klaus Koefoed , Lars Soegaard Nielsen , Per-Johan Meijer , Robert Carlsson
DOI:
关键词: Molecular biology 、 Polyclonal antibodies 、 Human cancer 、 Mechanism of action 、 Antibody 、 Anti-Epidermal Growth Factor Receptor Antibody 、 Biology 、 Recombinant antibodies 、 Recombinant DNA 、 Receptor
摘要: The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically provides compositions or mixtures capable binding EGFR. Antibody with 3 more have shown synergy reduction proliferation representative cell lines. Advantageous results also been obtained a composition comprising two different chimeric anti-hEGFR which show new mechanism action based on rapid and efficient receptor internalisation, induction terminal differentiation subsequent tumour eradication an animal model. can be manufactured one bioreactor as polyclonal antibody.